Pilatus Biosciences Inc. Secures FDA Orphan Drug Designation for PLT012: A Breakthrough in Liver and Intrahepatic Bile Duct Cancer Treatment ...Middle East

DOVER, Del. and EPALINGES, Switzerland, Dec. 10, 2024 /PRNewswire/ -- Pilatus Biosciences Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its leading molecule, PLT012, for treating liver and intrahepatic bile duct cancer...

Hence then, the article about pilatus biosciences inc secures fda orphan drug designation for plt012 a breakthrough in liver and intrahepatic bile duct cancer treatment was published today ( Wednesday 11/12/2024 - 06:16 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Pilatus Biosciences Inc. Secures FDA Orphan Drug Designation for PLT012: A Breakthrough in Liver and Intrahepatic Bile Duct Cancer Treatment )

Also on site :

• Cyberattack hits Canvas system used by thousands of schools as finals loom
• Philadelphia Soccer 2026 otvára akreditácie médií a registráciu fanúšikov na festival fanúšikov FIFA Fan Festival™ vo Philadelphii
• China Innovative Drug NHWD-870 Receives Breakthrough Therapy Designation, Bringing New Hope of Survival to NUT Carcinoma Patients